ApoPharma   Report issue

Contributed to NME For profit Phase 2 Phase 4
Founded: Toronto ON United States (2004)

Organization Overview

First Clinical Trial
2004
NCT00105495
First Marketed Drug
2011
deferiprone (ferriprox)
First NDA Approval
2011
deferiprone (ferriprox)
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

ApoPharma | ApoPharma Inc. | APOPHARMA INC

Active Ingredients

Marketed Drugs (1)

deferiprone (ferriprox) (2011 NDA)

Drugs in Phase 4 Trials (3)

deferiprone (ferriprox) (25 trials)

deferoxamine (desferal) (2 trials)

moxifloxacin (avelox) (1 trial)

Drugs in Phase 2 Trials (1)

orilotimod potassium (1 trial)

Indications

Approved Indications


 

Iron Overload

Thalassemia

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Anemia (Phase 4)

Anemia, Sickle Cell (Phase 4)

Ataxia (Phase 2)

beta-Thalassemia (Phase 4)

Cerebellar Ataxia (Phase 2)

Friedreich Ataxia (Phase 2)

Hemosiderosis (Phase 4)

HIV Infections (Phase 1)

Iron Overload (Phase 4)

Liver Diseases (Phase 4)

Motor Neuron Disease (Phase 2)

Nerve Degeneration (Phase 3)

Pantothenate Kinase-Associated Neurodegeneration (Phase 3)

Parkinson Disease (Phase 2)

Psoriasis (Phase 2)

Renal Insufficiency (Phase 4)

Sclerosis (Phase 2)

Thalassemia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial APIs: 4